{"id":28758,"date":"2025-03-05T18:42:33","date_gmt":"2025-03-05T10:42:33","guid":{"rendered":"https:\/\/flcube.com\/?p=28758"},"modified":"2025-03-05T18:42:35","modified_gmt":"2025-03-05T10:42:35","slug":"gensaic-and-novo-nordisk-team-up-to-develop-cardiometabolic-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=28758","title":{"rendered":"Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies"},"content":{"rendered":"\n

US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement with Denmark-based Novo Nordisk A\/S (NYSE: NVO<\/a>). The collaboration, combining Novo’s deep therapeutic knowledge and drug development experience with Gensaic’s novel protein design technology, is designed to discover tissue-targeting ligands and develop new therapeutic candidates to treat cardiometabolic disease via undisclosed targets.<\/p>\n\n\n\n

Financial Terms<\/strong>
Under the agreement, Gensaic is eligible to receive up to USD 354 million in upfront payments, development, and commercial milestones per target, plus tiered royalties. Novo will also reimburse research and development costs and participate in a future financing round. An executive of Novo will join Gensaic’s board as a non-voting observer member.<\/p>\n\n\n\n

Collaboration Details<\/strong>
Gensaic will be responsible for discovering novel protein ligands, while Novo Nordisk retains the rights to leverage these for further development. The collaboration includes Novo Nordisk’s license and option right to advance multiple therapeutic programs through research, development, and commercialization.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement…<\/p>\n","protected":false},"author":1,"featured_media":28761,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[99,69,3822,148,860],"class_list":["post-28758","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ai","tag-cvd","tag-gensaic","tag-novo-nordisk","tag-nyse-nvo"],"yoast_head":"\nGensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement with Denmark-based Novo Nordisk A\/S (NYSE: NVO). The collaboration, combining Novo's deep therapeutic knowledge and drug development experience with Gensaic's novel protein design technology, is designed to discover tissue-targeting ligands and develop new therapeutic candidates to treat cardiometabolic disease via undisclosed targets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=28758\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies\" \/>\n<meta property=\"og:description\" content=\"US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement with Denmark-based Novo Nordisk A\/S (NYSE: NVO). The collaboration, combining Novo's deep therapeutic knowledge and drug development experience with Gensaic's novel protein design technology, is designed to discover tissue-targeting ligands and develop new therapeutic candidates to treat cardiometabolic disease via undisclosed targets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=28758\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-05T10:42:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-05T10:42:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0505-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"480\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28758#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28758\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies\",\"datePublished\":\"2025-03-05T10:42:33+00:00\",\"dateModified\":\"2025-03-05T10:42:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28758\"},\"wordCount\":172,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28758#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/0505-png.avif\",\"keywords\":[\"AI\",\"CVD\",\"Gensaic\",\"Novo Nordisk\",\"NYSE: NVO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28758#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28758\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=28758\",\"name\":\"Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28758#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28758#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/0505-png.avif\",\"datePublished\":\"2025-03-05T10:42:33+00:00\",\"dateModified\":\"2025-03-05T10:42:35+00:00\",\"description\":\"US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement with Denmark-based Novo Nordisk A\\\/S (NYSE: NVO). The collaboration, combining Novo's deep therapeutic knowledge and drug development experience with Gensaic's novel protein design technology, is designed to discover tissue-targeting ligands and develop new therapeutic candidates to treat cardiometabolic disease via undisclosed targets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28758#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28758\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28758#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/0505-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/0505-png.avif\",\"width\":1080,\"height\":480,\"caption\":\"Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28758#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies - Insight, China's Pharmaceutical Industry","description":"US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement with Denmark-based Novo Nordisk A\/S (NYSE: NVO). The collaboration, combining Novo's deep therapeutic knowledge and drug development experience with Gensaic's novel protein design technology, is designed to discover tissue-targeting ligands and develop new therapeutic candidates to treat cardiometabolic disease via undisclosed targets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=28758","og_locale":"en_US","og_type":"article","og_title":"Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies","og_description":"US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement with Denmark-based Novo Nordisk A\/S (NYSE: NVO). The collaboration, combining Novo's deep therapeutic knowledge and drug development experience with Gensaic's novel protein design technology, is designed to discover tissue-targeting ligands and develop new therapeutic candidates to treat cardiometabolic disease via undisclosed targets.","og_url":"https:\/\/flcube.com\/?p=28758","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-05T10:42:33+00:00","article_modified_time":"2025-03-05T10:42:35+00:00","og_image":[{"width":1080,"height":480,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0505-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=28758#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=28758"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies","datePublished":"2025-03-05T10:42:33+00:00","dateModified":"2025-03-05T10:42:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=28758"},"wordCount":172,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=28758#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0505-png.avif","keywords":["AI","CVD","Gensaic","Novo Nordisk","NYSE: NVO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=28758#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=28758","url":"https:\/\/flcube.com\/?p=28758","name":"Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=28758#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=28758#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0505-png.avif","datePublished":"2025-03-05T10:42:33+00:00","dateModified":"2025-03-05T10:42:35+00:00","description":"US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement with Denmark-based Novo Nordisk A\/S (NYSE: NVO). The collaboration, combining Novo's deep therapeutic knowledge and drug development experience with Gensaic's novel protein design technology, is designed to discover tissue-targeting ligands and develop new therapeutic candidates to treat cardiometabolic disease via undisclosed targets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=28758#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=28758"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=28758#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0505-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0505-png.avif","width":1080,"height":480,"caption":"Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=28758#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0505-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28758","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=28758"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28758\/revisions"}],"predecessor-version":[{"id":28764,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28758\/revisions\/28764"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/28761"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=28758"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=28758"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=28758"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}